首页> 外文期刊>European urology >Intraprostatic and bladder-neck injection of botulinum a toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
【24h】

Intraprostatic and bladder-neck injection of botulinum a toxin in treatment of males with bladder-neck dyssynergia: a pilot study.

机译:前列腺内和膀胱颈注射肉毒杆菌毒素治疗男性膀胱颈功能不全的男性:一项初步研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To determine if intraprostatic and bladder-neck injection of botulinum toxin A (BoNTA) in patients with bladder-neck dyssynergia (BND) is a feasible alternative therapy. METHODS: Males diagnosed with BND on video-urodynamics showing delayed and incomplete bladder-neck opening during voluntary voiding were recruited. Eight consenting patients had 100U of BoNTA injected transurethrally into the bladder neck and proximal prostatic urethra laterally (10U/mlx10 sites). Patients were assessed at preinjection, at 1, 6, and 2 wk, and at 4 weekly intervals thereafter by means of uroflometry, 3-d frequency-volume chart, and International Prostate Symptom Score (IPSS)-Quality of life (QoL) questionnaire. Urodynamic studies were done at screening and 6 wk postprocedure. RESULTS: The mean age was 36.9 yr. Mean duration of symptoms was 6.5 yr. At 6 wk, 7 of 8 (87.5%) patients had>50% reduction of IPSS from baseline. Overall mean reduction was 50% (19.9+/-2.7 vs. 9.9+/-1.7, p=0.036). Six of 8 (75.0%) patients had>3ml/s increase in peak urinary flow rate with overall mean peak urinary flow rates improving from 11.6 to 17.2 (p=0.048) at 6 wk. Micturition frequency decreased 46% (13.6 vs. 7.6, p=0.036) and IPSS-QoL scores improved 47% (4.9+/-0.2 vs. 2.6+/-0.6, p=0.048). None reported any adverse effects or ejaculation dysfunction. Three of 8 patients had recurrence of symptoms after a mean of 8 mo. CONCLUSION: These results are encouraging. Larger, randomized, placebo-controlled trials could be worthwhile to verify these results.
机译:目的:确定膀胱颈功能不全(BND)患者前列腺内和膀胱颈注射肉毒毒素A(BoNTA)是否可行。方法:招募了通过视频尿流动力学诊断为BND的男性,该男性表现出自愿排尿过程中膀胱颈开放延迟和不完全。八名同意的患者经尿道经尿道注射100U BoNTA到膀胱颈和前列腺近侧尿道(10U / mlx10个部位)。患者在注射前,1、6和2周以及之后每4周进行一次尿量测定,3-d频率-容积图和国际前列腺症状评分(IPSS)-生活质量(QoL)调查表,对患者进行评估。在筛查和术后6周进行尿动力学研究。结果:平均年龄为36.9岁。平均症状持续时间为6.5年。在第6周,8名患者中有7名(87.5%)的IPSS较基线降低了50%以上。总体平均减少率为50%(19.9 +/- 2.7与9.9 +/- 1.7,p = 0.036)。 8名患者中有6名(75.0%)的峰值尿流率增加> 3ml / s,6周时总平均尿流率从11.6提高到17.2(p = 0.048)。排尿频率降低了46%(13.6 vs. 7.6,p = 0.036),IPSS-QoL评分提高了47%(4.9 +/- 0.2 vs. 2.6 +/- 0.6,p = 0.048)。没有人报告有任何不良反应或射精功能障碍。 8例患者中有3例在平均8个月后出现症状复发。结论:这些结果令人鼓舞。更大,随机,安慰剂对照的试验可能值得验证这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号